Juvenile Arthritis (JIA)
FDA-approved biologic treatments for children with juvenile idiopathic arthritis
Key Takeaways
- JIA is the most common chronic rheumatic disease of childhood — affecting ~300,000 children in the US
- Several biologics are FDA-approved specifically for pediatric JIA
- Early aggressive treatment improves long-term outcomes and reduces joint damage
- BiologicHealthPlus handles insurance, prior authorization, and delivery for pediatric biologic patients
What Is Juvenile Idiopathic Arthritis?
Juvenile idiopathic arthritis (JIA) is a group of chronic inflammatory joint diseases occurring in children under 16 years of age that persists for more than 6 weeks. JIA encompasses several distinct subtypes — including oligoarticular, polyarticular (RF-positive and RF-negative), systemic, psoriatic, enthesitis-related, and undifferentiated — each with different clinical features, disease course, and treatment approaches.
FDA-Approved Biologics for JIA
| Medication | JIA Subtype | Min Age |
|---|---|---|
| Humira (adalimumab) | Polyarticular JIA | 2 years |
| Enbrel (etanercept) | Polyarticular JIA | 2 years |
| Orencia (abatacept) | Polyarticular JIA | 6 years (IV); 2 years (SQ) |
| Actemra (tocilizumab) | Systemic JIA, Polyarticular JIA | 2 years |
| Cosentyx (secukinumab) | Enthesitis-related, Psoriatic JIA | 2 years |
| Rinvoq (upadacitinib) | Polyarticular JIA, Enthesitis-related, Psoriatic JIA | 12 years |
FDA-approved biologics for JIA have been studied specifically in pediatric populations and have demonstrated acceptable safety profiles in clinical trials. Long-term registry data for Humira and Enbrel in pediatric patients spans over 15 years. Your child's pediatric rheumatologist will carefully weigh the benefits and risks based on your child's specific JIA subtype, disease activity, and health history.
Most commercial insurance plans and Medicaid cover FDA-approved biologics for JIA with prior authorization. Children's Medicaid (CHIP) programs in most states also cover approved JIA biologics. BiologicHealthPlus handles all pediatric JIA prior authorizations and verifies your child's coverage at no charge. Manufacturer copay programs also provide significant savings for commercially insured families.
Not necessarily. Some children with JIA achieve sustained remission and are able to discontinue biologic therapy under close pediatric rheumatology supervision. The likelihood of remission depends on JIA subtype — oligoarticular JIA has higher remission rates, while RF-positive polyarticular JIA often requires long-term treatment. Your child's rheumatologist will guide decisions about medication tapering and discontinuation.
👨👩👧 BiologicHealthPlus Supports Families Managing JIA
We handle insurance, prior authorization, and copay enrollment for pediatric JIA patients — and our pharmacists are available 24/7 for parents with questions.
Get Support →Medical Disclaimer: Educational information only. Pediatric JIA treatment must be managed by a pediatric rheumatologist. Last updated: July 2026.